Company Information

Market Presence in over 70 Countries and Regions

The network of Takeda spans over 70 countries and regions worldwide, in Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific Region. Takeda's pharmaceutical products are marketed in around 100 countries worldwide, including partnerships (marketing alliance partners).

Takeda's Consolidated Revenue by region (FY 2016)

Japan: 655.3 billion yen
United States: 520.2 billion yen
Europe and Canada: 279.7 billion yen
Russia/CIS: 57.5 billion yen
Latin America: 72.5 billion yen
Asia: 112.8 billion yen
Others: 34.0 billion yen
(As of March 31, 2017)

30,000 Employees Worldwide

Takeda is accelerating development of talent with a global perspective and promotion of diversity; at the same time, building a sustainable organization by creating a work environment that allows employees to thrive and grow, as well as cultivating a corporate culture in which employees can resolutely tackle the challenge of drug discovery.

We will fulfill our responsibility as a company committed to improving people's lives by continuing to globalize our organization and promote diversity.

Each Takeda company around the world conducts corporate citizenship activities in tandem with its business activities, working to tackle the issues faced by local communities and building partnerships with NGOs and NPOs.
(As of March 31, 2017)

Since 1781

For more than 230 years, Takeda has developed its business with integrity while undergoing a process of continuous transformation.

Takeda began operations in 1781 when Chobei Takeda I started a business selling traditional Japanese and Chinese medicines in Doshomachi, Osaka. Takeda has been supplying pharmaceuticals for over 230 years, during which time we have developed a strong commitment to the highest ethical standards and a strong sense of mission. We have made constant efforts to improve our relationship with society over this time. As we move forward, we will continue to fulfill our responsibilities as a global pharmaceutical company.